



PRIOR AUTHORIZATION POLICY

POLICY: Neurology – Relyvrio Prior Authorization Policy

- Relyvrio™ (sodium phenylbutyrate and taurursodiol powder for oral suspension – Amylyx)

REVIEW DATE: 11/15/2023

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Relyvrio, a combination product of sodium phenylbutyrate and taurursodiol, is indicated for the treatment of **amyotrophic lateral sclerosis** (ALS) in adults.¹

Guidelines

The American Academy of Neurology practice parameter on the care of patients with ALS (last updated 2009; reaffirmed 2023) does not yet address Relyvrio; Radicava is also not addressed.^{2,3} The practice parameter states that riluzole is safe and effective for slowing disease progression to a modest degree and should be offered to patients with ALS. However, riluzole may result in fatigue in some patients and if the risk of fatigue outweighs modest survival benefits, discontinuation of riluzole may be considered. Referral to a specialized multidisciplinary clinic should be considered for patients with ALS to optimize health care delivery, prolong survival, and enhance quality of life. Additionally, noninvasive mechanical ventilation may lengthen survival and can be considered to improve quality of life and slow forced vital capacity decline. The European Federation of Neurological Societies guidelines on the clinical management of ALS (2012) also recommend patients be offered treatment with riluzole as early as possible after diagnosis.⁴ However, patients with progressive muscular atrophy, primary lateral sclerosis, or hereditary spastic paraplegia should not be treated with

riluzole. New guidelines on the management of ALS were presented at the European Academy of Neurology 2023 meeting and are expected to be published before the end of 2023.⁵ The recommendations during this meeting stated the riluzole should be offered lifelong to all ALS patients at diagnosis and a single daily dose of 50 mg can be effective.⁷ The Canadian best practice recommendations for the management of ALS state that riluzole has demonstrated efficacy in improving survival in ALS and there is evidence that riluzole prolongs survival by a median duration of 3 months.⁶ Riluzole should be started soon after the diagnosis of ALS.

POLICY STATEMENT

Due to the lack of clinical efficacy data, **approval is not recommended** for Relyvrio.

CONDITIONS NOT COVERED

Relyvrio™ (sodium phenylbutyrate and taurursodiol powder for oral suspension (Amylyx) is considered experimental, investigational or unproven for ANY use including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

- 1. Amyotrophic Lateral Sclerosis (ALS).** Approval is not recommended due to the unclear clinical benefit of Relyvrio and lack of clinical efficacy data.⁷ The preliminary evidence demonstrates a potentially minimal clinical benefit that is confounded to interpret (e.g., two-point difference in the ALS functional rating scale – revised [ALSFRS-R] mean score). The efficacy data for Relyvrio are not convincing and have many limitations in analysis. Results from the ongoing Phase III trial (PHOENIX) are needed to determine whether Relyvrio provides clinically meaningful benefit in patients with ALS and to more clearly define an appropriate population for this therapy.

REFERENCES

1. Relyvrio™ oral suspension [prescribing information]. Cambridge, MA: Amylyx; September 2022.
2. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). *Neurology*. 2009 (reaffirmed 2020);73(15):1227-1233.
3. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). *Neurology*. 2009;73:1218-1226.
4. Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. *Eur J Neurol*. 2012;19(3):360-375.
5. New EAN Guidelines on ALS Management. Physician's Weekly. July 10, 2023. Available at: <https://www.physiciansweekly.com/new-ean-guidelines-on-als-management/>. Accessed on August 3, 2023.

6. Shoesmith C, Abrahao A, Benstead T, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. *CMAJ*. 2020;192(46):E1453-E1468.
7. Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. *N Engl J Med*. 2020 Sep 3;383(10):919-930.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	10/19/2022
Selected Revision	Amyotrophic Lateral Sclerosis (ALS): This condition was moved from the Recommended Authorization Criteria to the Conditions Not Covered because of the unclear clinical benefit of Relyvrio and lack of clinical efficacy data.	01/04/2023
Annual Revision	No criteria changes.	11/15/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna